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Background: The present experiment was conducted to identify the cooperative effect of serine histogranin 
(SHG) and noradrenaline in alleviating peripheral neuropathic pain.
Methods: Chronic constriction injury of the right sciatic nerve was used to induce chronic neuropathic pain. 
For drug delivery, a PE10 tube was inserted into the subarachnoid space. Acetone drops and a 44oC water 
bath were used to evaluate the cold and heat allodynia, respectively. Placing and grasping reflexes were used 
to assess the locomotor system. 
Results: SHG at 0.5 and 1 μg significantly (P ＜ 0.05) decreased the thermal allodynia. The cold allodynia 
was also significantly reduced by intrathecal injections of 0.5 (P ＜ 0.05) and 1 μg (P ＜ 0.001) of SHG. 1 
μg of noradrenaline, but not 0.5 μg, significantly alleviated the cold (P ＜ 0.01) and thermal (P ＜ 0.05) 
allodynia. The ameliorating effect of noradrenaline or SHG disappeared when the two compounds were 
administrated in equal concentrations. A significant difference (P ＜ 0.01 in the acetone and P ＜ 0.05 in 
the heat) was observed in the groups under equal doses of the two compounds, with a lower effectiveness 
of the combination therapy. 
Conclusions: Our findings suggest that the simultaneous administrations of noradrenaline and SHG do not 
result in synergistic analgesia, and combination therapy may not be a good approach to the treatment of chronic 
neuropathic pain syndrome. (Korean J Pain 2015; 28: 96-104)
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INTRODUCTION
Neuropathic pain, which can be caused by nerve irri-
tation, damage, or destruction of the nervous system, is 
one of the six classes of chronic pain. It may be associated 
with abnormal sensations (dysesthesia), an exaggerated 
pain sensation (hyperalgesia), and pain produced by nor-
mally non-painful stimuli (allodynia). The mechanism of 
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neuropathic pain is not yet fully understood, and it is be-
lieved that a central or peripheral mechanism may be 
involved. Neuropathic pain is usually unresponsive to nor-
mal drug therapy, and there is a limited range of treatment 
available to patients [1,2]. 
Glutamate (glu) is the main neurotransmitter present 
in the terminals of afferent neurons specialized in pain 
transmission. The activity of glutaminergic neurons in the 
spinal cord is greatly increased by inflammation and neu-
ropathic pain conditions. Exaggerated glu activity through 
NMDA receptors is responsible for central sensitization 
[3,4].
It has been reported that the transplantation of the 
adrenal medullary gland into the subarachnoid space is ac-
companied by reduced pain-related behaviors in neuro-
pathic animals [5,6]. Catecholamines are the main prod-
ucts secreted by the adrenal medulla. It has been shown 
that the injection of α- adrenergic antagonists after 
transplantation of the adrenal medulla does not eliminate 
the analgesic effect of the transplant in the chronic phase 
of a formalin test. It has therefore been suggested that 
other factors secreted by this tissue play a role in the an-
algesic effect [6].
Histogranin with anti-NMDA activity is a peptide ex-
tracted from the chromaffin cells of the adrenal medulla. 
Histogranin is responsible for the partial analgesic effects 
of adrenal medullary transplantation in the spinal cord of 
neuropathic rats [6,7]. Several recent studies have reported 
a much higher efficacy from a precise multi-target combi-
nation therapy than from mono-therapy for the manage-
ment of neuropathic pain [3,8,9]. A considerable advantage 
of using combination therapy is that the active ingredients 
act on different molecular targets, which enables them to 
act on more of the signaling cascades involved in pain. 
Another major benefit of combination therapies is that 
they reduce the development of drug resistance. The main 
aim of this study was to investigate the analgesic effect 
of histogranin and noradrenaline in reducing neuropathic 
pain.
MATERIALS AND METHODS
Male Sprague-Dawley rats (250-300 g) were housed 
in separate cages with free access to food and water, and 
were exposed to light and dark cycles of 12：12 hours. All 
the procedures were approved by the institutional animal 
ethics committee.
1. Surgeries
To induce chronic constriction injury (CCI) of the sciatic 
nerve, the animals were anaesthetized with a mixture of 
intraperitoneal ketamine and xylasin (80 mg/kg and 10 
mg/kg, respectively) and the skin of their left hind paw was 
cleaned with 70% alcohol. The sciatic nerve was exposed 
at the mid-thigh portion, and was isolated from the sur-
rounding tissue. Four loose ligatures of the 4-0 chromic 
gut were tied around the sciatic nerve, one millimeter apart 
on the proximal part of the trifurcation. The wound was 
immediately closed with silk sutures, and a topical anti-
biotic was applied on top of the wound. One week after 
the surgery, the animals’ Basso-Beattie-Bresnahan (BBB) 
scores were assessed to confirm the CCI model induction. 
The rats with a BBB score over 2 points were excluded (the 
success rate was 96.3%). After confirmation of the CCI in-
duction, for cannulation, the animals were anaesthetized 
with the same anesthetic mixture. Their heads were fixed 
in a stereotaxic device and their hair was removed at the 
junction of the scalp and the first spinal vertebra. A 7.5 
cm PE 10 tube (Braintree Scientific, INC. Braintree, MA, 
USA) was carefully placed through a puncture in the middle 
of the atlanto-occipital membrane to the lumbar level of 
the spinal cord, and the wound was closed and treated with 
a topical antibiotic ointment. The rats were returned to 
their cages and were left to recover for 3 days. On the 
day of the drug injection, the forelimbs and hind limbs were 
monitored to check the motor deficits. The animals dis-
playing neurological deficits were excluded from further 
studies and were euthanized. The motor dysfunction and 
pain threshold was assessed 10 days after the surgery.
2. Behavioral assessment
An acetone test was used for the evaluation of cold 
allodynia. The rats were placed in a transparent plastic 
cage on a metal mesh surface for a habituation period of 
20 min. A drop of acetone was then squirted onto the 
mi-plantar surface of their hind paws. Brisk withdrawal, 
licking, or biting of the hind paw was defined as a positive 
response. The test was repeated 5 times at 5 min intervals. 
The frequency of the foot withdrawal was expressed as a 
percentage: (number of trials accompanied by brisk foot 
withdrawal) × 100 / (number of total trials).
For evaluation of the thermal pain, a paw immersion 
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test was used. The hind paws of the animals were carefully 
dried and immersed in a cup of freshly filled water at a 
temperature of exactly 44oC. The withdrawal time, i.e., the 
time between the immersion of the hind paw in the hot 
water and the withdrawal reaction, was recorded. A 
cut-off time of 20 sec was considered. The test was re-
peated twice, and the average withdrawal time was eval-
uated as the withdrawal latency.
The motor reflexes were evaluated through grasping 
and placing reflexes. For the evaluation of the grasping re-
flex, a horizontal stainless steel surface containing several 
bars measuring 2 mm in diameter and placed 1 cm apart 
was used. The rats were restrained with towels and were 
kept close to the surface, so that their hind paws touched 
the bars. The tonic grasp of the rats’ hind paws was 
tested. The trial was repeated 5 times, and the number 
of positive grasping responses was recorded.
For evaluation of the placing reflex, the rats were re-
strained with a towel and were kept close to the edge of 
a table, so that their hind paws were located slightly be-
neath the surface of the table. In the case of a positive 
placing reflex, the animal put the hind paw on top of the 
table. The experimenter recorded whether reflexive placing 
of the hind paws on the table surface occurred. The ex-
periment was repeated 5 times, and the number of positive 
responses was recorded.
3. Experimental design
Ten groups of rats (80 rats in total) were used to ex-
amine the analgesic effects of the administrated drugs. 
Four groups received intrathecal injections of different 
doses (0.5 and 1 microgram) of noradrenaline and serine 
histogranin (SHG). Four different groups of animals re-
ceived simultaneous injections of both drugs to investigate 
the effect of combination therapy. One group remained in-
tact (control group), and another group received normal 
saline as a vehicle. The behavioral assessment was con-
ducted (pre-injection) ten days after the induction of the 
nerve injury (3 days after cannulation), when the level of 
the pain was maximal, and the drugs were then injected 
intrathecally.
Fifteen minutes after the drug injection, the animals 
underwent a behavioral test (post-injection). The se-
quencing of the behavioral test was the same for all ex-
perimental groups, and the same individual, who was blind 
to the treatment, administered the drugs and tested the 
animals. Eight animals were used in each group.
4. Drugs
Noradrenaline was purchased from the Sigma-Aldrich 
Company and SHG was purchased from Bachem, Torrance, 
CA. All drugs were dissolved and diluted in saline, and were 
injected in a volume of 10 μl. The catheter was then flush-
ed with 10 μl of sterile saline. In the vehicle group, 20 μl 
of normal saline were injected. In the groups receiving in-
jections of both drugs, noradrenalin was injected immedi-
ately after injection of the SHG.
In order to investigate the additive or synergistic effect 
of noradrenaline and SHG, the effectiveness of each drug 
alone and in combination was determined by subtracting 
the post-injection values from the pre-injection values. To 
assess the theoretical additive effect of the two drugs, the 
values obtained from the subtraction for the groups re-
ceiving noradrenaline or SHG alone were summated. To 
evaluate the synergistic effect, the theoretical values of 
the additive effect were compared with the experimental 
values when administrated in combination.
5. Statistical analysis
All the data were presented as mean ± SEM. The 
statistical analyses were performed using the SPSS soft-
ware (version 16). A paired sample t-test was used to 
compare the variables between the groups, and an in-
dependent sample t-test was used to determine the syner-
gistic effect. A P value ＜ 0.05 was considered significant.
RESULTS
1. Effect of SHG and noradrenaline alone or in combination 
on the acetone test
The injury of the sciatic nerve significantly increased 
the response to acetone droplets (P ＜ 0.01). The admin-
istration of 1 μg of noradrenaline, but not of 0.5 μg, sig-
nificantly increased the percentage of response to the 
acetone drops (P ＜ 0.01). Both doses of SHG significantly 
alleviated the allodynic response to the acetone droplets 
(P ＜ 0.05 for 0.5 μg and P ＜ 0.001 for 1 μg). No sig-
nificant difference between the pre- and post-injection 
values was observed in the vehicle group (P = 0.4) (Fig. 1A). 
The combination therapy in all doses effectively decreased 
the cold allodynia induced by the acetone drops. The com-
bination of noradrenaline and SHG in all doses brought 
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Fig. 1. Percentage of withdrawal response to the acetone 
drops in the drug-treated CCI groups, vehicle-treated 
CCI group, and control animals (A,  B). The comparison 
between the theoretical effectiveness and the effecti-
veness of the experimental combination therapy is shown 
in (C). The combination therapy decreased the effecti-
veness of the treatment. The results are expressed as 
the mean ± SEM of the 8 animals in each group. *P ＜
0.05, **P ＜ 0.01, ***P ＜ 0.001; NA: noradrenaline, 
SHG: serine histogranin.
about a significant increase in the percentage of responses 
(P ＜ 0.01) (Fig. 1B). Fig. 1C shows the comparison between 
the theoretical effectiveness and the effectiveness of the 
combination therapy. A significant difference was observed 
between the co-administration of 1 μg of noradrenaline 
with 1 μg of SHG and the theoretical effectiveness. In the 
case of simultaneous administration, the percentage of re-
sponse to the acetone test was significantly lower than the 
theoretical effectiveness (P ＜ 0.01) (Fig. 1C).
2. Effect of SHG and noradrenaline alone or in combination 
on the withdrawal latencies from the 44oC water
The injury of the sciatic nerve significantly decreased 
the paw withdrawal latency response to the 44oC water (P 
＜ 0.001). When administrated alone, both doses of SHG 
(P ＜ 0.05) and 1 μg of noradrenaline (P ＜ 0.05) sig-
nificantly increased the withdrawal latency. The injection 
of 0.5 μg of noradrenaline had no significant effect (P = 
0.19). The vehicle injection did not change the withdrawal 
response (P = 0.71) (Fig. 2A). In the groups receiving 1 μg 
SHG + 0.5 μg noradrenaline (P ＜ 0.01) and 0.5 μg SHG 
+ 1 μg noradrenaline (P ＜ 0.05), a significant increase in 
the withdrawal latency was observed. In the animals that 
received 0.5 μg of noradrenaline + 0.5 μg of SHG (P = 
0.94) and 1 μg of noradrenaline + 1 μg of SHG (P = 0.11), 
no significant difference was observed between the pre- 
and post-injection values (Fig. 2B). However, in the com-
parison between the theoretical effectiveness and the ef-
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Fig. 2. Withdrawal latencies in response to the 44oC 
water in the drug-treated CCI groups, vehicle-treated 
CCI group, and control animals (A, B). The comparison 
between the theoretical effectiveness and the effec-
tiveness of the experimental combination therapy is 
shown in (C). The effectiveness was significantly reduced 
in the case of combination therapy with equal doses. The 
results are expressed as the mean ± SEM of the 8 
animals in each group. *P ＜ 0.05, **P ＜ 0.01; NA: 
noradrenaline, SHG: serine histogranin.
fectiveness of the combination therapy, a significant dif-
ference was observed in the groups that had received 0.5 
μg of noradrenaline + 0.5 μg of SHG (P ＜ 0.05) and 1 
μg of noradrenaline + 1 μg of SHG (P ＜ 0.05) (Fig. 2C).
3. Effect of SHG and noradrenaline alone or in combination 
on the motor reflexes
The chronic constriction of the sciatic nerve sig-
nificantly blocked the animals’ grasping and placing re-
flexes, and a significant reduction of those reflexes was 
observed on the second week following CCI (P ＜ 0.001). 
The injection of vehicle, noradrenaline, or SHG alone or in 
combination did not improve the reflexes (P ＞ 0.05), and 
no significant difference was observed in the number of 
grasping and placing reflexes between the pre- and 
post-injection of the drugs (P ＞ 0.05) (Fig. 3). In the 
comparison between the theoretical effectiveness and the 
effectiveness of the combination therapy, no significant 
difference was observed (P ＞ 0.05) (not shown).
DISCUSSION
Noradrenaline and SHG are two substances secreted 
by the adrenal medulla. The results of the present study 
show that both compounds can block the maintenance of 
CCI-induced allodynia. Moreover, the results of this study 
confirm that loose constriction of the sciatic nerve pro-
duces motor and sensory disorders in the affected limb(s). 
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Fig. 3. Changes in the number of positive grasping (A, B) and placing reflexes (C, D) after intrathecal injection of 
noradrenaline (NA) or serine histogranin (SHG), alone or in combination, in the different experimental groups. The drug
therapy did not improve the motor reflexes. The results are expressed as the mean ± SEM of the 8 animals in each group.
The grasping and placing reflexes disappeared following 
sciatic nerve injury, and the injection of SHG or nora-
drenaline alone or in combination did not enable recovery 
of the reflexes. The key finding of the present study is that 
the simultaneous administration of SHG and noradrenaline 
does not have a synergistic effect in increasing the pain 
threshold. This was made clear by the two compounds ad-
ministrated in equal concentrations in the CCI model. The 
data show that in equal doses, noradrenaline and SHG have 
a sub-additive effect or antagonize one another’s effect 
(Fig. 2C).
Histogranin has been shown to have anti-NMDA 
activity. NMDA antagonists have an analgesic effect in 
acute and chronic pain models and can augment opioid an-
algesia and reduce the development of tolerance to opioids 
[10]. It is known that the intrathecal injection of SHG, the 
stable analog of SHG, in a concentration of 1 microgram 
attenuates the hyperalgesia and allodynia resulting from 
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chronic constriction injury of the sciatic nerve in rats. The 
administration of 2 and 4 micrograms of SHG has a lower 
analgesic effect in the CCI model [7]. This means that 
higher doses of SHG are not substantially more potent 
than lower doses in the neuropathic pain model, which in-
dicates a dual role (agonist -antagonist) of the peptide. 
The noradrenaline transporter in the spinal cord in-
creases at the lumbar level of the spinal cord after a nerve 
injury [11], which shows that the level of noradrenaline in 
the lumbar level decreases following nerve injury. There-
fore, it seems that the decrease in the content of nora-
drenaline in the spinal cord in the neuropathic pain con-
dition is one of the main mechanisms in the pathophysiol-
ogy of neuropathic pain [12]. Chronic nerve injury produces 
neuropathic pain by increasing the excitability of the dorsal 
horn neuron of the spinal cord, and this excitability can 
be reduced by an alpha 2 receptor agonist [13]. 
There has been growing interest in using drug combi-
nation therapy for the alleviation of chronic pain [3,4,8,9]. 
The effect of the two drugs in combination could be super 
additive or synergistic if the results of their actions were 
higher than the results expected from their individual po-
tencies and efficacies. In contrast to synergism, some 
drugs may act antagonistically when their simultaneous 
administration shows subadditivity [14,15]. Among anti-
nociceptive drugs, NMDA antagonists have been the main 
center of attention for the treatment of neuropathic pain. 
However, due to their side effects when administrated 
alone and in effective doses, they are not the first choice 
for the treatment of neuropathic pain syndromes. 
It has been reported that the burning pain and allody-
nia observed in complex regional pain syndrome could be 
treated with the administration of an alpha 2 agonist, dex-
medetomidine, and an NMDA antagonist such as ketamine. 
No side effects have been reported for this combination 
therapy [16]. Adrenergic receptor agonists respectively ac-
tivate and inhibit K+ channels and voltage-dependent Ca++ 
channels, and alter the firing rates of neurons [17]. From 
the results obtained in this study, it appears that the single 
administration of noradrenaline or SHG can be sufficiently 
effective to block nociception, with no adverse effects. It 
seems that when administrated in combination, SHG and 
noradrenaline do not show a superadditive effect in the 
chronic constriction model of the sciatic nerve. The mech-
anism of the interaction between the adrenergic system 
and the NMDA receptors remains to be elucidated. The 
changes in the pharmacokinetics of each drug may be 
caused by their co-administration. For example, nora-
drenaline may induce vasoconstriction and decrease the 
spinal blood flow, thereby influencing the pharmacokinetics 
of other drugs [18]. A second possibility is that the two 
substances act on the same site. Subadditive interaction 
usually occurs when two compounds have affinity for one 
receptor and affect different critical points along a com-
mon pathway. The third possibility is that one compound 
affects the release of the other. Glutamate receptors, 
which are located presynaptically, generally mediate the 
control of neurotransmitter release [19]. The release-en-
hancing glutamate receptors are isolated from the nora-
drenergic nerve terminals [20]. The mutual interactions 
between glutamate receptors and NMDA receptors have 
been investigated by several researchers [21,22]. Presy-
naptic NMDA receptors have been found on the neocortical 
noradrenergic nerve terminals of rats and humans [23]. 
Therefore, it seems likely that presynaptic NMDA receptors 
and metabotropic glutamate receptors interact to modulate 
the noradrenaline release from noradrenergic terminals. 
Luccini et al. showed that NMDA receptors enhance nora-
drenaline release when in combination with metabotropic 
glutamate receptors [22]. The authors’ results demon-
strated that in a Mg2+ free solution, NMDA agonists di-
rectly act on the noradrenergic axon terminals at the level 
of the presynaptic NMDA receptors, and enhance the re-
lease of noradrenaline. According to the results of the 
present study, it is likely that SHG prevented or decreased 
the secretion of noradrenaline by the nerve terminals, an 
effect mediated by presynaptic NMDA receptor inhibition. 
There seems to be a mutual relation between the NMDA 
receptors and the adrenergic receptors. It has been re-
ported that exogenous alpha agonists have a neuro-
protective effect in retinal excitotoxicity models. Alpha 2 
receptors located postsynaptically are able to modulate the 
NMDA receptor function. This mechanism is responsible for 
the neuroprotective effect of exogenous alpha 2 agonists 
[24].
With regard to the interactions of the adrenergic and 
NMDAergic systems, Nishiyama et al. reported a syner-
gistic effect on the pain threshold from an alpha adrener-
gic agonist and an NMDA antagonist, going against the re-
sults of this study. In Nishiyama et al., clonidine was used 
as the alpha 2 adrenergic receptor agonist, and AP-5 as 
the NMDA receptor antagonist [25]. In addition, in two 
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previous studies, Horvath et al. showed that ketamine and 
S(+)-ketamine, but not R(-)-ketamine (an NMDA antago-
nist), exhibited a similar effectiveness in potentiating the 
antinociceptive effects of dexmedetomidine (an α2-adren-
oceptor agonist) [26,27]. As NMDA receptors have multiple 
agonist binding sites on the various NMDA receptor sub-
units, using different substances may exert different 
effects. Moreover, the types of behavioral tests used in the 
experiments may explain the differences in the results be-
tween the two studies. In Horvath et al.’s study, a tail flick 
and formalin test was used for the behavioral evaluation. 
This is the most traditional test of nociception and is based 
on stimulus intensity. The tail flick test evaluates phasic, 
short-lasting pain behavior, and is therefore unsuitable for 
the evaluation of tonic or chronic pain, which are modu-
lated differently in the central nervous system. The pain 
induced by formalin injections is a more temporary kind 
of tonic pain, which presents a distinct mechanism from 
chronic pain.
In conclusion, the intrathecal administration of nora-
drenaline or SHG as an adrenergic receptor agonist and 
an NMDA receptor antagonist, respectively, increases the 
pain threshold in the neuropathic pain model induced by 
chronic constriction injury of the sciatic nerve. The simul-
taneous administration of both compounds however does 
not produce synergistic analgesia, and no effect has been 
observed on motor behavior. These results suggest that 
combination therapy using adrenergic and NMDAergic sys-
tems may not be a good approach to the treatment of 
chronic neuropathic pain syndrome.
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